Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Monopar Therapeutics Inc. MNPR
$0.92
-$0.01 (-1.47%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
13161536.00000000
-
week52high
4.88
-
week52low
0.95
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.99913500
-
EPS
-0.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 16 авг 2022 г. |
| HC Wainwright & Co. | Buy | 01 ноя 2021 г. | |
| Roth Capital | Buy | 28 янв 2021 г. | |
| Maxim Group | Buy | 24 сент 2020 г. | |
| Brookline Capital | Buy | 19 февр 2020 г. | |
| EF Hutton | Buy | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Robinson Chandler | A | 326907 | 169012 | 01 февр 2023 г. |
| Robinson Chandler | A | 221839 | 221839 | 01 февр 2023 г. |
| Brown Michael J | A | 10133 | 10133 | 01 февр 2023 г. |
| Brown Michael J | A | 13930 | 13930 | 01 февр 2023 г. |
| Anderson Raymond | A | 10133 | 10133 | 01 февр 2023 г. |
| Anderson Raymond | A | 13930 | 13930 | 01 февр 2023 г. |
| Tsuchimoto Kim R | A | 135382 | 78234 | 01 февр 2023 г. |
| Tsuchimoto Kim R | A | 102688 | 102688 | 01 февр 2023 г. |
| KLAUSNER ARTHUR J | A | 10133 | 10133 | 01 февр 2023 г. |
| KLAUSNER ARTHUR J | A | 13930 | 13930 | 01 февр 2023 г. |
Новостная лента
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Zacks Investment Research
18 ноя 2022 г. в 15:11
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tissue sarcoma.
Monopar's stock gains 13% after completing enrollment for an experimental therapy for cancer patients
Market Watch
05 окт 2022 г. в 08:50
Shares of Monopar Therapeutics Inc. MNPR, +6.92% gained 13.5% in premarket trading on Wednesday after the company said it completed enrollment in a Phase 2b clinical trial evaluating its experimental therapy aimed at preventing severe oral mucositis in patients undergoing chemoradiotherapy for oropharyngeal cancer. Monopar expects to have interim data from this study in the first quarter of next year.
Monopar Therapeutics Inc. (MNPR) Could Find Support Soon, Here's Why You Should Buy the Stock Now
Zacks Investment Research
18 авг 2022 г. в 11:18
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.